Tirzepatide — is that Mounjaro? Yes, and here's what that means

You searched for tirzepatide and landed on a Mounjaro page, that is not a mistake

This happens constantly. A question our prescribers hear most weeks goes roughly: "I read about tirzepatide in a news article, then searched for it, and everything came up as Mounjaro, are they actually the same thing or am I missing something?" The answer is straightforward. Tirzepatide is the generic scientific name (technically an International Non-proprietary Name, or INN) for the molecule itself. Mounjaro is the brand name Eli Lilly chose when it brought that molecule to market in the UK.

It works the same way whatever you call it. The pen you inject once a week contains tirzepatide. The clinical trials that generated the evidence (including SURMOUNT-1, whose results the NICE technology appraisal TA1026 drew on) referred to the drug as tirzepatide throughout. When your prescriber writes the prescription, tirzepatide is what appears in the notes. The Mounjaro KwikPen is simply the delivery device Lilly built around it.

The distinction matters practically when you are doing research. Searching "tirzepatide" returns clinical literature and regulatory documents; searching "Mounjaro" returns the branded product pages. Both lead to the same medicine. If you want to understand whether to think of this as Mounjaro or tirzepatide, and what the difference actually means in practice, that page works through the relationship between the two names in detail. If you want to understand more about what tirzepatide actually is and how it was developed, that page goes into the science in more depth.

What makes tirzepatide different from other weight-loss injections

Most GLP-1 receptor agonists work on one pathway. Tirzepatide targets two: the GLP-1 receptor and the GIP receptor. GIP stands for glucose-dependent insulinotropic polypeptide, a gut hormone involved in appetite signalling and metabolic regulation. Activating both receptors at once is why tirzepatide is described as a dual agonist, and it is the only medicine in that class currently licensed for weight management in the UK, as confirmed by the NHS tirzepatide medicines page.

In the SURMOUNT-1 trial (2,539 adults with obesity, 72 weeks) participants on the 15 mg dose achieved around 20 to 21 per cent average body-weight reduction. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly against semaglutide 2.4 mg and found tirzepatide produced greater average weight loss. These are trial-population averages; individual results vary, and no medicine works the same way for every person.

Treatment starts at the 2.5 mg dose (a starting level designed to let your system adjust rather than a therapeutically active target) and a prescriber titrates upward from there, typically in four-week steps through 5, 7.5, 10, 12.5 and 15 mg. Dosing decisions are always made by the prescriber, not the patient acting alone. If you are still wondering whether tirzepatide is simply another name for Mounjaro or something more complicated, that page works through the question in full.

Who the UK licence covers and how the NHS fits in

The licensed eligibility for private prescribing follows the SmPC: adults, BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone does not decide the outcome; the prescriber assesses the full clinical picture.

On the NHS, NICE TA1026 sets stricter criteria. Currently access is phased: from June 2025, adults with a BMI of 40 or above plus four or more specific conditions qualify under the first cohort; from around June 2026, the BMI threshold drops to 35 with the same comorbidity requirement. Private treatment through a regulated online pharmacy is the alternative for people outside those parameters or unwilling to wait. If cost is part of your thinking, the Mounjaro cost page explains what private pricing typically looks like and what drives the variation between providers.

Tirzepatide is a Black Triangle medicine in the UK, meaning the MHRA is actively collecting additional safety data. That status is standard for newer medicines and does not indicate a problem, it reflects the regulator doing its job. All side effects, including any you would not necessarily connect to the medicine, can be reported at the MHRA's Yellow Card scheme.

Getting a prescription: what the process looks like

Because tirzepatide (Mounjaro) is a prescription-only medicine, the only legal route is a clinical assessment followed by a prescriber's decision. There is no shortcut. Through nume, the process runs as follows: you complete a free consultation online, a GPhC-registered Independent Prescriber reads your answers the same day, identity and weight are verified, and if you are clinically suitable the pen is dispatched with free next-working-day DPD delivery in plain packaging. Every repeat order goes through the same clinical review, nothing is automatic.

Knowing that tirzepatide and Mounjaro are the same substance is genuinely useful before that consultation. It means the clinical literature you have read and the prescription your prescriber writes are describing identical things. If you want a broader overview of tirzepatide as a medicine before taking the next step, that page covers the mechanism, the trial programme and the UK licence in one place. Alternatively, our Mounjaro overview page covers the branded product from a practical, patient-facing angle.

Ready to find out whether you are eligible? Speak to our prescribers through a free consultation and get a same-day clinical review.